Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
This article was originally published in RPM Report
Executive Summary
Patient advocates are pushing the Food & Drug Administration to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.
You may also be interested in...
Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years
PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.
COVID-19 Vaccine ‘Booster’ Or Simply A Third Dose? US FDA’s Marks Starts To Reframe The Issue
It’s a classic example of an internal dispute between an FDA review team and agency leadership playing out at an advisory committee forum, except with the highest possible stakes.
Pazdur To Oncology Drug Developers: Step Back, Slow Down – And Find The Right Dose
FDA’s “Project Optimus” draft guidance on dose optimization is in the works. Until then, randomized dosing studies need to be an IND-level conversation.